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ABSTRACT
Sporadic dementia of Alzheimer’s type (SDAT) pathogenesis has not been 
revealed completely due to the difficulty in creating an appropriate animal 
model. The purpose of this study was to investigate the effect of single-dose 
intraperitoneal (IP) induction of streptozotocin (STZ) and lipopolysaccharide 
(LPS) on the β-amyloid levels and the brain function of experimental rats. 
Eighteen rats were divided into three groups i.e. control, TRE1 (STZ 60 mg.kg-1 
BW + LPS 3 mg.kg-1 BW), and TRE2 (STZ 30 mg.kg-1 BW + LPS 1.5 mg.kg-1 BW). 
The substances were administered in a single dose. Behavioral tests were 
started at day-30 after injection, we performed Morris water maze (MWM) 
and novel object recognition (NOR) tests. Afterward, we measured whole brain 
and serum β-amyloid levels, as one of the biomarkers of Alzheimer’s Disease 
(AD), using the ELISA method. In MWM tests, the escape latency and time spent 
in the target quadrant of treatment groups were significantly higher than 
those in control at the day-5 MWM test and probe trial. The rats in treatment 
groups have negative discrimination indexes in NOR tasks, indicating that 
the rats could not remember the familiar object. Intraperitoneal STZ and LPS 
significantly increase soluble brain β-amyloid levels of treatment groups than 
those in the control group. In conclusion, the treatment of STZ (60 mg.kg-1 BW) 
and LPS (3 mg.kg-1 BW) indicated spatial and recognition memory impairment, 
along with an increase of brain soluble β-amyloid level in rats. 
ABSTRAK
Patogenesis tipe demensia Alzheimer sporadis (SDAT) belum terungkap 
sepenuhnya karena hambatan dalam menemukan hewan model yang sesuai. 
Tujuan penelitian ini adalah untuk mengkaji efek induksi streptozotocin (STZ) 
dan lipopolisakarida (LPS) secara intraperitonial (IP) pada tingkat β-amiloid dan 
fungsi otak tikus percobaan. Delapan belas tikus dibagi menjadi tiga kelompok 
yaitu kontrol, TRE1 (STZ 60 mg.kg-1 BB. + LPS 3 mg.kg-1 BB), and TRE2 (STZ 30 
mg.kg-1 BB + LPS 1.5 mg.kg-1 BB). Zat tersebut diberikan dalam dosis tunggal. Uji 
perilaku dimulai pada hari ke-30 setelah injeksi, menggunakan uji Morris water 
maze (MWM) dan Novel object recognition (NOR). Setelah itu, kadar β-amiloid 
pada otak dan serum diukur menggunakan metode ELISA sebagai salah satu 
biomarker penyakit Alzheimer (AD). Hasil penelitian menunjukkan bahwa 
latensi dan durasi tikus di kuadran target untuk kelompok perlakuan secara 
signifikan lebih tinggi daripada tikus kontrol pada uji MWM hari ke-5 dan uji 
Probe trial. Tikus dalam kelompok perlakuan memiliki indeks diskriminasi 
negatif dalam uji NOR, menunjukkan bahwa tikus tidak dapat mengingat 
objek yang dikenalnya. STZ dan LPS secara signifikan meningkatkan kadar 
β-amiloid otak pada kelompok perlakuan dibandingkan kelompok kontrol. 
Dapat disimpulkan, perlakuan STZ (60 mg.kg-1 BB) dan LPS (3 mg.kg-1 BB) 
menyebabkan gangguan memori spasial dan rekognisi, serta meningkatkan 
kadar β-amiloid terlarut pada otak tikus.
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INTRODUCTION
Dementia is generally described as 
a cognitive impairment that is severe 
enough to disturb social or job-related 
brain function.1 According to the cause 
of dementia, there are four common 
subtypes of dementia-Alzheimer’s 
disease (AD), vascular, frontotemporal, 
and Lewy body dementia.2  The most 
common cause of dementia is AD, 
which is estimated at 60 to 80% of 
cases.3 The first symptom of dementia 
is memory dysfunction, a weakening in 
ability for consolidation and recall of 
newly received information.4  Disorder 
of episodic and semantic memory 
systems are the main indication of AD.5,6 
Hippocampus, that crucial in episodic 
memory system, is reduced its volume in 
AD.7 Memory deterioration in AD tends 
to be anterograde amnesia subsequently 
retrograde amnesia, the lack of ability to 
create novel memories and regain old 
memories, respectively.8 
More than 90% of patients with AD 
seem to be sporadic and to have old 
onset.9 Amyloid protein precursor (APP), 
presenilin-1 (PSEN1), and presenilin-2 
(PSEN2) mutations are involved in 
early-onset AD pathogeny.10 Typical 
late-onset AD is probably due to the 
complex interaction between genetic 
and environmental factors.11  Several 
hypotheses  have been proposed to 
explain AD pathogenesis - cholinergic, 
amyloid, tau protein, and apolipoprotein 
ε4 hypothesis.12,13 Among others, 
β-amyloid plaque and neurofibrillary 
tangles are implicated in AD pathogenesis 
and is a key element of the present 
etiology hypotheses.11 
Commonly, the laboratory animal 
models are established on the familial 
AD-linked mutations that yielding in 
Aβ level increase and accumulation.14 
Meanwhile, transgenic models for 
sporadic AD, such as the APOE ε4 gene 
mutation in mice and those in primates, 
are severely limited by availability issues 
and costs. Since 90% of cases of AD are 
sporadic, the opportunity for developing 
non-GMO animal models is wide open. 
Streptozotocin is first known for 
its anti-cancer activity, then being used 
as an induction agent to create a model 
for diabetes.15 Streptozotocin moves 
into pancreatic beta-cell, induce DNA 
alkylation, and eventually generate 
cell necrosis.16 Cellular toxicity of 
STZ is supposed to be facilitated by 
increasing reactive oxygen species 
(ROS) in mitochondria that stimulate the 
oxidative stress of the cells.17  Several 
metabolic pathways known to induce 
these cellular stress are polyol pathway, 
hexosamine pathway, diacylglycerol-
activated protein kinase C  (PKC), and 
advanced glycation end products (AGE) 
formation.18 
Streptozotocin enters the cell via 
protein transporter GLUT2, the main 
glucose carrier in several organs, 
including the brain.19,20 The particular 
mechanism  on how STZ affecting 
the brain is still being investigated. 
Moreover, the effect of combination of 
intraperitoneal STZ and LPS on brain 
function is still unknown. The study 
aimed to investigate the effect of single-
dose intraperitoneal (IP) induction of STZ 
60 mg.kg-1 BW and lipopolysaccharide 
(LPS) 3 mg.kg-1 BW on the β-amyloid levels 
and the brain function of experimental 
rats as a model of sporadic dementia.
MATERIALs AND METHODS
Animals
Wistar rats (Rattus norvegicus 
Berkenhout, 1769) from the Integrated 
Research and Testing Laboratory, 
Universitas Gadjah Mada, Yogyakarta 
were housed at colony cages contained 
wood chip bedding with standard pellet 
food and tap water ad libitum. The room 
environment  was  maintained  in constant 
temperature (26-27oC) and humidity 
(76-88%) on a 12 h light/dark cycle. The 
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protocol  of study was approved by the 
Research Ethic Committee for Preclinical 
Research, Universitas Gadjah Mada  (Ref. 
00030/04/LPPT/VI/2019).
Materials
Streptozotocin was obtained from 
Cayman Chemical (Ann Arbor, MI, 
USA) and was dissolved in a citrate 
buffer. Lipopolysaccharide (LPS) from 
Escherichia coli 055:B5 was purchased 
from Sigma-Aldrich (St. Louis, MO, 
USA). Ketamine was obtained from 
Troy Laboratories (Glendenning, NSW, 
Australia) and Xylazine was obtained 
from Interchemie (Metaalweg, Venray, 
Holland). All other chemicals were of 
analytical grade and obtained from 
standard commercial suppliers.
Animal treatments
Rats were separated into three 
groups, each containing six rats. The 
control group (CNT) was given 1 mL 
distilled water (placebo), the second 
group of rats received IP injection of 
STZ (60 mg.kg-1 BW) and LPS (3 mg.kg-1 
BW), meanwhile the third group of 
rats received IP injection of STZ (30 
mg.kg-1 BW) and LPS (1.5 mg.kg-1 
BW). All substances mentioned were 
administered using a 27 G syringe in a 
single dose.
MWM test
Morris water maze (MWM) tasks 
were performed in a black-colored 
circular tank (diameter, 1.5 m) filled with 
tap water (30-32 oC). The start or finish 
platform was built from 10 x 10 x 15 cm 
clear glass cube. The swimming path was 
recorded using video camera B-PRO5α 
fixed focus F2.8 f= 3 mm 170o wide-angle 
lens (Brica, China) and analyzed using 
Idtracker 2.1 (Cajal Institute, Madrid, 
Spain). The task was carried out for five 
consecutive days consisted of training 
trial, probe trial, and visual cue trial.21 
For day one training, the rat was located 
in the tank at four random quadrants 
with a visible platform. On day two until 
four, training trials were performed 
with the hidden (submerged) platform. 
The latency for individual training 
was documented. The probe test was 
conducted on day 5. In the probe trial, 
rat was left to dip in the tank for one min 
devoid of the platform. The duration in 
the target (platform location) quadrant 
was noted. In the visual cue test, the 
platform was returned into the visible 
condition and the latency was recorded.
NOR test
Novel object recognition (NOR) tasks 
were carried out for four days which 
included familiarization, habituation, 
and test day.22  In familiarization, a rat 
was placed in the test cage box (40 x 40 
x 40 cm, black colored) for 5 min. In the 
subsequent day, the habituation was 
performed by introduced a rat with 
two identical objects in 5 min duration 
for two consecutive days. Then the test 
day was done by replacing one object 
with another object of different shape 
and color. The duration of the test was 
limited to 60 sec. Discrimination index 
(DI) was quantified by comparing the 
duration spent by the rat to sniff on new 
objects and that on the initial object.
Blood collection
Blood and brain samples were 
collected after behavioral tests. Before 
blood and brain collection, animals 
were anesthetized with i.m. ketamine 
(50 mg.kg-1 BW) and xylazine (20 mg.kg-1 
BW) cocktail.  Whole blood samples 
were collected from retro-orbital sinus, 
coagulated for 15 min, and spun using 
Centrifuge 5418R (Eppendorf, Hamburg, 
Germany) at 4,000 rpm for 15 min at 
4oC. The supernatant was collected and 
stored under -20 oC for further analysis.
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Blood glucose level and body weight
Blood glucose levels and body 
weights of rats were measured on the day-
30 after STZ-LPS administration. Plasma 
glucose levels using amperometric 
glucose meter Easytouch GCU (Bioptik 
Technology, Taiwan). Meanwhile, 
body weights were measured using an 
analytical balance (Ohaus Instrument, 
Shanghai, China).
Brain collection
For brain collection, anesthetized 
animals were dissected until the heart 
exposed. Perfusion was then performed 
with a cannula located in the cor (left 
ventricle). Afterward, the right atrium 
was incised and the descending thoracic 
aorta was clamped. Perfusion was done 
using cold phosphate-buffered saline 
with heparin sodium (PT. Pratapa 
Nirmala, Tangerang, Indonesia) at 1,000 
IU.mL-1 concentration. Subsequently, 
animal skulls were opened until the 
brain completely exposed. The whole 
brain was isolated and kept on ice for 
further homogenization.
β-amyloid extraction
β-amyloid extraction was performed 
based on the modified β-amyloid 
extraction protocol by Casali and 
Landreth.23  Fresh isolated whole brain 
tissues were mechanically homogenized 
using Handheld Homogenizer MT-
13K (Huangzhou Miu Instrument 
Ltd, Zhejiang, China) at 18,000 
rpm for 2 min in cold 850µL tissue 
homogenization buffer (2 mM Tris and 
pH 7.4); 250 mM sucrose; 0.5 mM EDTA 
(Ethylenediaminetetraacetic acid); 0.5 
mM; H2O) containing fresh protease 
inhibitor cocktail on ice. For soluble 
β-amyloid extraction, 250µL brain 
homogenates were added with 250 µL 
0.4% diethylamine then spun at 14,000 
rpm for 1 h at 4oC. Obtained supernatants 
(extracts) were neutralized with 42.5 µL 
0.5 M Tris-HCl (pH 6.8), were frozen in 
liquid nitrogen, and were kept in the 
freezer for soluble β-amyloid analysis. 
Meanwhile, the pellet homogenates were 
added with 125µL cold formic acid, were 
mixed using a vortex, and were spun 
at 14,000 rpm for 1 h at 4oC. Afterward, 
105µL supernatants (extracts) were 
mixed with 1.895mL of formic-acid 
neutralization buffer (1 M Tris base; 0.5 
M Na2HPO4; 0.05% NaN3), were frozen 
in liquid nitrogen, and were kept at the 
freezer for insoluble β-amyloid analysis.
β-amyloid quantification
Frozen serum and brain extracts 
were thawed before performing the assay. 
Serum and brain-derived β-amyloid 
were quantified using Enzyme-Linked 
Immunosorbent Assay (ELISA) method, 
according to assay procedure of Fine Test 
ELISA Rat Amyloid-β 40 Kit (Wuhan Fine 
Biological  Technology, Hubei, China) 
with catalog number: ER0754. Samples 
were analyzed in duplo. Optical density 
(OD value) of standards and samples 
were measured using a Microplate 
Reader Elx800 (Biotek Instruments, 
Vermont, USA) set to 450 nm.
Statistical analysis
All data were statistically evaluated 
using SPSS 22.0 (IBM corporation, USA). 
We used the oneway ANOVA (analysis 
of variance) and Tuckey test to analyze 
MWM latencies, NOR index, soluble 
brain β-amyloid, blood glucose levels, 
and body weights. Meanwhile, we used 
Kruskal-Wallis test and Kruskal-Wallis 
Pairwise Comparison for soluble brain 
β-amyloid and serum β-amyloid. The 
results were considered significant at 
p<0.05.
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RESULTS
MWM test
In the MWM test, rats form a spatial 
memory using visual stimuli around 
the chamber. Memory was assessed 
by the duration before the animal find 
the platform (escape latency) and by 
the proportion of the duration in the 
platform area (target quadrant). Escape 
latencies of the rats in each group were 
observed during the MWM test. Latency 
data were normally distributed. The 
results of the ANOVA and Tuckey test 
showed there was a significant variation 
in escape latency at training day-5 
(FIGURE 1A). The escape latencies in 
the TRE1 rats were significantly longer 
than those in the CNT group (p<0.05). 
The swimming trajectories of the rats in 
the CNT group were smooth and direct 
into the escape platform. Meanwhile, the 
swimming trajectories of TRE1 and TRE2 
rats were disorganized (FIGURE 2A). 
The probe trial was conducted on 
training day-5 to assess spatial memory. 
Data were normally distributed. The 
time spent in the target quadrant of 
TRE1 and TRE2 rats were significantly 
shorter than those in CNT rats (p<0.05) 
according to the ANOVA and Tuckey test 
(FIGURE 1B). Movement trajectories of 
rats at the MWM Probe Trial showed a 
disorganized path in TRE1 and TRE2 rats 
(FIGURE 2B).
To asses that MWM results were not 
affected by sensorimotor function, we 
used the MWM visual cue test. The visual 
cue test was conducted after the MWM 
probe trial on day 5 of training. Latency 
data were normally distributed. The 
ANOVA analysis showed no significant 
sensorimotor function effects on visual 
cue parameters (FIGURE 1A).
FIGURE 1. Escape latencies and time in target quadrant in MWM tasks. (A) Escape 
latencies of TRE1 rats were significantly longer than those in CNT rats at 
the day-5 MWM test using an invisible platform (##, p<0.05, ANOVA, Tuckey 
Test). Meanwhile, escape latencies during Visual Cue Test using MWM 
visible platform were not significant among all groups of treatments (p>0.05, 
ANOVA). (B) Time spent in the target quadrant of TRE1 and TRE2 rats were 
significantly shorter than those in CNT rats at MWM Probe trial (##, p<0.05, 
ANOVA, Tuckey test). CNT: control group; TRE1: STZ 60 mg.kg-1 BW and LPS 
3 mg.kg-1 BW; TRE2: STZ 30 mg.kg-1 BW and LPS 1.5 mg.kg-1 BW. Data are 
presented as mean (×) and median with upper and lower quartiles, min and 
max values and outliers (o). n=6.
BA
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FIGURE 2. Representative movement trajectories of rats in all groups during MWM tasks. 
(A) The swimming trajectories of the rats in the CNT group were smoother 
and more direct than those in other groups that were disorganized at MWM 
Day-5. (B) Movement trajectories of rats at MWM Probe Trial showed a 
disorganized path in TRE1 and TRE2 rats. Platform was removed during 
Probe Trial. CNT: control group; TRE1: STZ 60 mg.kg-1 BW and LPS 3 mg.kg-1 
BW; TRE2: STZ 30 mg.kg-1 BW and LPS 1.5 mg.kg-1 BW.
NOR test
In the NOR test, the variations in the 
exploration duration of new (unfamiliar) 
and familiar objects were observed. We 
measured it using DI i.e. the deviation 
in the exploration period of a novel 
(unfamiliar) and familiar object, then 
comparing the score by the entire 
duration of exploration. DI of TRE1 and 
TRE2 rats showed negative scores, lower 
than those in CNT rats (p < 0.05) (FIGURE 3).
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FIGURE 3. Discrimination index of TRE1 and TRE2 rats showed negative score, lower 
than those in CNT rats during NOR test (##, p<0.05, ANOVA, Tuckey test). 
CNT: control group; TRE1: STZ 60 mg.kg-1 BW and LPS 3 mg.kg-1 BW; 
TRE2: STZ 30 mg.kg-1 BW and LPS 1.5 mg.kg-1 BW. Data are presented 
as mean (×) and median with upper and lower quartiles, min and max 
values and outliers (o). n=5 for all groups.
Blood glucose level and body weight
Blood glucose contents and body 
weights of each group were measured on 
the day-30 after STZ-LPS administration 
(TABLE 1). Circulating glucose levels of 
the TRE1 rats were significantly higher 
than those in CNT and TRE2 rats (p<0.05). 
Meanwhile, the body weights of the TRE1 
rats were significantly lower than those 
in other groups (p<0.05).
TABLE 1. Blood glucose and body weight of rats in all 
groups (mean ± SEM.)
Groups Blood glucose (g.dL-1) Body weight (g)
CNT 113.33 ± 19.40 191.48 ± 5.36
TRE1 198.00 ± 30.83  ## 149.44 ± 13.01  ##
TRE2 71.67 ± 9.00  n.s 187.53 ± 6.57  n.s
CNT: control group; TRE1: STZ 60 mg.kg-1 BW and LPS 
3 mg.kg-1 BW; TRE2: STZ 30 mg.kg-1 BW and LPS 1.5 
mg.kg-1 BW; ##: significant to CNT (p<0.05 ANOVA, 
Tuckey test); n.s.: not significant to CNT; n=6
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β-amyloid level
Soluble and insoluble brain 
β-amyloid levels in each group of rats 
were measured (TABLE 2). Soluble brain 
β-amyloid levels in TRE1 rats (509 ± 41 
pg.mL-1) and TRE2 rats (536 ± 36 pg.mL-1) 
were significantly higher than those in 
CNT rats (326 ± 44 pg.mL-1), according to 
ANOVA and Tuckey test (p<0.05). Data 
were normally distributed. The highest 
Individual soluble brain β-amyloid level 
was 750.09 pg.mL-1 (TRE1). Meanwhile, 
insoluble β-amyloid levels in TRE1 rats 
(324 ± 33 pg.mL-1) were higher than CNT 
rats (287 ± 18 pg.mL-1) and TRE2 rats (310 
± 23 pg.mL-1) but not significant (p>0.05).
TABLE 2. Brain and serum β-amyloid levels of rats in all groups (mean ± SEM)
Groups
Brain β-amyloid Serum β-amyloid (pg.
mL-1)Soluble (pg.mL-1) Insoluble (pg.mL-1)
CNT 326.45 ± 44.34 287.06 ± 18.26 436.91 ± 44.70
TRE1 508.50 ± 40.59## 323.73 ± 33.48n.s 503.73 ± 130.49n.s
TRE2 535.77 ± 36.24## 310.09 ± 23.11n.s 250.09 ± 31.01n.s
CNT: control group; TRE1: STZ 60 mg.kg-1 BW and LPS 3 mg.kg-1 BW; 
TRE2: STZ 30 mg.kg-1 BW and LPS 1.5 mg.kg-1 BW; ##: significant to CNT 
(p<0.05 ANOVA, Tuckey test); n.s.: not significant to CNT; n=4
Serum β-amyloid levels in each 
group of rats were measured following 
termination. The highest mean was in 
TRE1 group (504±130 pg.mL-1) comparing 
with CNT (437±45 pg.mL-1). Kruskal 
Wallis test showed that serum β-amyloid 
levels in TRE1 rats were not significant 
than those in CNT rats (p>0.05).
DISCUSSION
Memory dysfunction can be used 
as an early indicator of dementia. 
This condition can lead to an amnesic 
syndrome, a condition when an 
individual unable to consolidate and 
retrieve memory.24 This failure causes 
the conditions of anterograde and 
retrograde amnesia. The type of memory 
that is affected in dementia is episodic 
memory, a subtype of declarative 
memory. Hippocampus and part of the 
temporal medial lobe are believed to 
play a major role in the formation of 
episodic memories, one of them is spatial 
memory. This function is conducted by 
the ‘place cells’ located in the CA1 and 
CA3 parts of the hippocampus.25 To assess 
the ability to store and retrieve spatial 
memories, we used the MWM memory 
test. In addition, we also used the NOR 
test to assess the performance of another 
declarative memory i.e. recognition 
memory.
We used MWM to assess 
hippocampus plasticity without affected 
by external motivation like food. The 
escape latencies in the TRE1 rats were 
significantly longer than those in the 
CNT group (p<0.05), indicated the 
learning capacity was decreased after 
STZ and LPS treatment. Previous studies 
showed that AβOs disrupt excitatory 
synaptic function, suppress long-term 
potentiation, and facilitating long-term 
depression.14 Moreover, in MWM probe 
trial showed consistent results where 
the durations in the target quadrant 
were lower in the treatment groups. The 
difference in sensorimotor performance 
can be neglected as we found no 
significant result in MWM visual cue test. 
In addition to the MWM, the rats 
were subjected to a NOR task, that also 
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hippocampus-dependent learning tasks. 
Discrimination indexes of TRE1 and 
TRE2 rats were negative, it means that 
the rats spent less time exploring the 
novel object. Furthermore, ANOVA and 
Tuckey’s test showed a significant result 
of DI in TRE1 and TRE2 rats than those 
in CNT rats, indicating that the rats 
could not remember the familiar object 
(p<0.05).
β-amyloid has a pivotal role in the 
pathobiology of AD. Both brain or other 
cells-derived β-amyloid fragment are 
created by the separation of Amyloid 
Precursor Protein (APP) initially after 
β-Site APP-cleaving enzyme 1 (BACE1) 
to produce C99 fragment and soluble 
APPβ, then the C99 fragment is separated 
by γ-secretase to yield β-amyloid.26 
Generally, there are two types of 
β-amyloid, insoluble β-amyloid fibrils 
(fAβ) and soluble oligomers (nonfibrillar) 
β-amyloid (AβO). Therefore, in the 
present research, we examine the 
soluble and insoluble form of β-amyloid 
after STZ and LPS administration. In 
the past decade, fAβ that constructs the 
extracellular plaques was proposed to 
be a major pathogenic factor of AD as 
amyloid cascade hypothesis.27  However, 
recent findings in animal models and 
humans suggest that the accumulation 
of AβO have the same neurotoxic effects. 
These findings have established the AβO 
hypothesis.14
Our recent findings showed a 
significant increase in soluble brain 
β-amyloid, but no significant result 
in insoluble brain β-amyloid. Recent 
studies suggest that soluble β-amyloid, 
such as oligomers, ADDLs, globulomers, 
and protofibrils, may cause neurons 
injury.28  Soluble β-amyloid enter neurons 
and initiate autophagy. Insufficient 
destruction of β-amyloid aggregates by 
autophagy may occur inside the neurons, 
resulting in lipofuscin accumulation that 
could worsen neuronal dysfunction.29 
An electrophysiological study showed 
that amyloid deposition lowering 
the long-term potentiation (LTP) in 
the hippocampus, both stimulation 
and preservation.30 LTP weakness is 
correlated with low performance of 
individuals in memory tasks.
The results showed that IP STZ 
and LPS significantly increase soluble 
β-amyloid level. Since systemic STZ 
cannot penetrate blood-brain barrier 
due to lack of GLUT-2 receptors, STZ 
may influence brain metabolism 
indirectly, through alteration free 
fatty acid (FFA) level in blood or 
other substance that may toxic to the 
brain.15 Meanwhile, LPS administration 
causes neuroinflammation, including 
acute (until day-7) soluble β-amyloid 
increase.31 However, LPS alone did not 
hold β-amyloid at high levels in sub-acute 
response.32 Therefore, our findings may 
be promising since β-amyloid increase 
was lasting until 30 days after single STZ 
and LPS injections.
We tried to elucidate the potential 
of chemical-induced animal models of 
dementia, which are more pertinent 
to the sporadic type of AD. Several 
pharmacological substances have also 
used to induce SDAT, they are ferrous 
amyloid buthionine, okadaic acid, 
Aluminium chloride, scopolamine, and 
trimethyltin.33-35 Those substances were 
considered for the testing hypothesis 
of AD – cholinergic, tau protein, or 
amyloid. Our results suggested that STZ 
and LPS combination impaired memory 
performance and increase the soluble 
β-amyloid level as a hallmark of AD, 
which particularly tests the amyloid 
hypothesis of AD. Together with other 
chemical-induced models, a combination 
of STZ and LPS may participate in the 
current treatment development for 
AD. However, further molecular and 
electrophysiological research needs to 
be conducted to uncover the pathological 
mechanism of SDAT. Moreover, research 
using experimental animals is basic 
research that still has a long journey to 
be applied in humans.
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CONCLUSION
The results showed that 
intraperitoneal  injection of STZ 
(60 mg.kg-1 BW) and LPS (3 mg.kg-1 
BW) indicate decrease in memory 
performance and increase soluble 
β-amyloid level in rats. These findings 
suggest that the treatment is prospective 
for SDAT non-transgenic animal model.
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